Phio Pharmaceuticals' cancer treatment results are strong, causing the stock price to soar

Investing.com – Phio Pharmaceuticals Corp (NASDAQ:PHIO) stock surged 57.8% in pre-market trading on Tuesday after the company reported strong efficacy results from its Phase 1b clinical trial.

This clinical-stage siRNA biopharmaceutical company announced that its INTASYL compound PH-762 achieved an 85% pathological response rate in the final cohort, with 6 out of 7 patients responding to the treatment. Among the six responders, four experienced complete responses, with a tumor clearance rate of 100%.

Importantly, no serious adverse events or dose-limiting toxicities were observed in any of the five dose-escalation cohorts, which included 22 enrolled patients who completed four intratumoral injections of PH-762.

Phio Pharmaceuticals President and CEO Robert Bitterman stated, “These results support further evaluation of the highest concentration of PH-762 in the next clinical trial.”

The company reported an overall response rate of 65% in squamous cell carcinoma (cSCC). Out of 20 cSCC patients, 13 were classified as pathological responders, including 9 with complete responses, 2 with major/nearly complete responses, and 2 with partial responses.

Phio plans to submit a proposal to the FDA in Q2 2026 seeking guidance on the next steps for clinical study design. The company is also advancing its chemistry, manufacturing, and control development, with materials expected to be available for non-human primate studies by March 2026, a necessary step before initiating pivotal human trials.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.